Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.

The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio.